Aratana Therapeutics To Participate At Two Upcoming Investor Conferences
LEAWOOD, Kan., May 23, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at Stifel Dental & Veterinary Conference on Wednesday, June 1 at 10:55 a.m. ET in New York City and at Jefferies Healthcare Conference on Tuesday, June 7 at 2:30 p.m. ET in New York City.
The Jefferies Healthcare Conference will be webcast and interested parties may listen live or access the audio link for up to 90 days after the meeting. Presentation slides from the conference will also be available in the Aratana Investor Room.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for dogs and cats. Aratana believes that it can leverage the investment in the human pharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company has multiple products approved by the Food and Drug Administration's Center for Veterinary Medicine or licensed by the United States Department of Agriculture. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious, unmet or underserved medical needs. Aratana believes providing innovative options to veterinarians and pet owners will help manage pets' medical needs safely and effectively, result in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
Logo - http://photos.prnewswire.com/prnh/20160425/359503LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-participate-at-two-upcoming-investor-conferences-300272936.html
SOURCE Aratana Therapeutics, Inc.
